
    
      A randomized, double-blind, placebo-controlled study.

      Participants: Pregnant women over 18 years of age with serologically proven, primary CMV
      infection during the first trimester

      Intervention: After informed consent and randomization, participants in the treatment group
      will receive Valacyclovir at a dose of 8 g/d. Participants in the control group will receive
      the same amount of daily pills containing placebo. Treatment will continue until
      amniocentesis, which will determine if the fetus was infected.
    
  